The Idiopathic Pulmonary Fibrosis (IPF) treatment market has witnessed significant growth over the past decade, driven by rising prevalence, increasing awareness about early diagnosis, and the introduction of advanced therapies. IPF is a chronic, progressive lung disease characterized by scarring of lung tissues, leading to irreversible loss of lung function and respiratory failure....